Here, the authors identify activation of PI3K/mTOR and CREB pathways as a driver of GC-resistance in BCP-ALL and restore sensitivity using the multi kinase inhibitor, dasatinib. The gene discussed is CREB1; the disease is acute lymphoblastic leukemia.